683 Capital Management LLC Purchases New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

683 Capital Management LLC bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 69,000 shares of the company's stock, valued at approximately $919,000. 683 Capital Management LLC owned 0.26% of Eton Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Nantahala Capital Management LLC lifted its holdings in shares of Eton Pharmaceuticals by 12.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company's stock valued at $14,898,000 after purchasing an additional 119,750 shares in the last quarter. Cannell Capital LLC bought a new position in Eton Pharmaceuticals in the fourth quarter worth approximately $5,079,000. Geode Capital Management LLC boosted its stake in shares of Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock worth $1,637,000 after acquiring an additional 32,365 shares during the last quarter. Aristides Capital LLC grew its position in shares of Eton Pharmaceuticals by 20.8% during the 4th quarter. Aristides Capital LLC now owns 241,587 shares of the company's stock valued at $3,218,000 after acquiring an additional 41,587 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Eton Pharmaceuticals by 230.5% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock worth $2,862,000 after purchasing an additional 149,864 shares in the last quarter. Institutional investors own 27.86% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ETON. B. Riley reissued a "buy" rating and set a $24.00 price target (up previously from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Craig Hallum increased their target price on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a "buy" rating in a report on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ:ETON traded up $0.44 during trading on Wednesday, hitting $17.07. 54,241 shares of the company's stock were exchanged, compared to its average volume of 181,578. The business's 50-day simple moving average is $14.34 and its 200 day simple moving average is $13.41. Eton Pharmaceuticals, Inc. has a 52-week low of $3.18 and a 52-week high of $18.41. The company has a market cap of $457.78 million, a price-to-earnings ratio of -77.29 and a beta of 1.22.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02). The firm had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. On average, sell-side analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.